Kurt Diebold

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Peter A. Fasching, Carsten Denkert, Mahdi Rezai, 2016, Clinical Cancer Research.

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Carsten Denkert, Manfred Dietel, C. Denkert, 2013, PloS one.

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Carsten Denkert, Christine Solbach, K. Dietrich, 2012, Breast Cancer Research and Treatment.